Insider sold ELVN at $30… stock is now $38 – does this actually matter?

Saw an interesting insider transaction on Enliven Therapeutics (ELVN). The Chief Medical Officer exercised and sold 40,000 shares at around $30.07, for about $1.2 million total.

What makes it interesting is timing. The stock recently closed around $38.83, which is roughly 28% higher than where those shares were sold.

At first glance, it looks like bad timing or even a bearish signal. But digging deeper, this was an exercise-and-sell transaction, not a typical open market sale. That usually means it’s more about liquidity or compensation than a directional bet on the stock.

Also worth noting: she still holds 25,000 shares plus over 180,000 stock options, so exposure to the company is still significant.

Looking at the bigger picture, ELVN is a clinical-stage biotech with no profits yet, reporting about -$103M net income (TTM). The stock is up roughly 84% over the past year, which explains why insiders might take some money off the table.

For traders, insider sales like this can create short-term hesitation. For long-term investors, especially in biotech, these events are often less meaningful than clinical trial progress or pipeline updates.

So the real question is:

Do you treat insider selling in biotech as a signal, or just noise compared to trial data and catalysts?

Not financial advice.